Compare FUL & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUL | ZLAB |
|---|---|---|
| Founded | 1887 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2007 | 2017 |
| Metric | FUL | ZLAB |
|---|---|---|
| Price | $60.17 | $25.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $68.40 | $49.60 |
| AVG Volume (30 Days) | 570.1K | ★ 851.0K |
| Earning Date | 03-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | 19.57 | ★ 38.46 |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $2,897,000,000.00 | $460,156,000.00 |
| Revenue This Year | $4.96 | $9.75 |
| Revenue Next Year | $4.00 | $26.03 |
| P/E Ratio | $38.53 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $48.71 | $15.96 |
| 52 Week High | $68.63 | $36.77 |
| Indicator | FUL | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 76.57 |
| Support Level | $58.21 | $16.98 |
| Resistance Level | $62.04 | $27.23 |
| Average True Range (ATR) | 1.63 | 1.10 |
| MACD | 0.72 | 0.75 |
| Stochastic Oscillator | 75.11 | 85.87 |
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. It generates the maximum revenue from hygiene, health, and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven, and hygiene (disposable diapers, feminine care, and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.